Page 539

U.S. Notes (con.) (b) For imported articles subject to headings 9903.04.60–9903.04.68 that are eligible for special tariff treatment under any of the free trade agreements or preference programs listed in general note 3(c)(i) to the tariff schedule, the duties provided in these headings shall be collected in addition to any special rate of duty otherwise applicable under the appropriate tariff subheading. Goods for which entry is claimed under a provision of chapter 98 of the HTSUS and which are subject to the additional duties prescribed herein shall be eligible for and subject to the terms of such provision and applicable U.S. Customs and Border Protection (“CBP”) regulations. No claim for entry or for any duty exemption or reduction shall be allowed under a provision of chapter 99 of the HTSUS that may set forth a lower rate of duty or provide duty-free treatment, taking into account information supplied by CBP. All antidumping, countervailing, or other duties and charges applicable to such goods shall continue to be imposed. (c) The headings provided in subdivision (a) of this note and the defined terms of this subdivision apply to articles that are classifiable in the following provisions of the HTSUS: [Compiler's note: List may begin on subsequent page; read numbers from left to right.] 2922.29.2700 2922.19.0900 2921.49.4300 2921.49.3800 2918.99.3000 2925.29.2000 2924.29.6250 2922.50.2500 2922.50.1400 2922.49.2600 2933.19.3500 2932.20.2000 2931.90.2200 2930.90.9235 2928.00.3000 2933.49.2600 2933.39.4100 2933.29.4500 2933.29.2000 2933.19.4500 2933.59.5900 2933.59.5300 2933.59.4600 2933.59.3600 2933.59.2100 2933.99.5590 2933.99.5300 2933.99.4600 2933.79.8500 2933.79.0800 2933.99.9000 2933.99.7500 2933.99.7000 2933.99.6500 2933.99.6100 2935.90.4800 2934.99.4700 2934.99.3000 2934.30.2700 2934.30.2300 2937.22.0000 2937.19.0000 2937.12.0000 2937.11.0000 2935.90.6000 2937.23.5050 2937.23.5020 2937.23.5010 2937.23.1050 2937.23.1010 2937.90.4500 2937.50.0000 2937.29.9095 2937.29.9050 2937.29.9040 2939.19.5000 2939.19.2000 2939.11.0000 2938.90.0000 2937.90.9000 2942.00.0500 2941.90.5000 2941.90.3000 2941.90.1050 2941.10.5000 3002.14.0090 3002.14.0010 3002.13.0090 3002.13.0010 3002.12.0040 3002.49.0050 3002.42.0000 3002.41.0000 3002.15.0091 3002.15.0011 3002.90.5250 3002.90.5220 3002.90.1000 3002.59.0000 3002.51.0000 3003.49.0000 3003.39.5000 3003.39.1000 3003.31.0000 3003.20.0000 3004.10.1010 3003.90.0190 3003.90.0180 3003.90.0140 3003.90.0120 3004.32.0060 3004.31.0000 3004.20.0083 3004.20.0010 3004.10.5010 3004.49.0010 3004.49.0005 3004.41.0000 3004.39.0055 3004.39.0010 3004.49.0060 3004.49.0050 3004.49.0040 3004.49.0030 3004.49.0020 3004.90.9206 3004.90.9201 3004.90.1000 3004.50.5005 3004.49.0070 3004.90.9216 3004.90.9215 3004.90.9211 3004.90.9210 3004.90.9208 3004.90.9249 3004.90.9246 3004.90.9243 3004.90.9236 3004.90.9225 3004.90.9263 3004.90.9260 3004.90.9253 3004.90.9252 3004.90.9251 3004.90.9273 3004.90.9271 3004.90.9270 3004.90.9268 3004.90.9267 3004.90.9276 For the purposes of this note: (i) “Pharmaceutical articles” refers to imported articles classifiable in the provisions enumerated in this subdivision that are pharmaceutical products or that are ingredients (active pharmaceutical ingredients and key starting materials) classifiable in the provisions enumerated in this subdivision used to make pharmaceutical products. (ii) “Patented pharmaceutical articles” are pharmaceutical articles that are subject to a valid, unexpired U.S. patent and are listed in the U.S. Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”) or in the FDA’s Lists of Licensed Biological Products (“Purple Book”); and ingredients (active pharmaceutical ingredients and key starting materials) for such articles. (iii) “Generic pharmaceutical articles” are FDA-approved pharmaceutical articles, and associated ingredients, that are not subject to a valid, unexpired U.S. patent and are off exclusivity. A generic pharmaceutical article is an active pharmaceutical ingredient or any component in a finished dosage form product that is used in a drug product or biosimilar biological product approved pursuant to a qualifying application; or a drug product or biosimilar biological product approved or licensed pursuant to a qualifying application. A qualifying application is: (a) an abbreviated new drug application submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (“FDCA”); (b) a new drug application submitted under section 505(b)(2) of the FDCA that has been requested to be or that has been deemed therapeutically equivalent to a listed drug; (c) a biosimilar biologics application submitted under section 351(k) of the Public Health Services Act; or (d) an application for an authorized generic drug or authorized biological product, as those terms are described in section 505(t) of the FDCA and 42 U.S.C. § 1320f-1(e)(2)(B)(ii), provided that the products are imported by a generic or biosimilar manufacturer. Harmonized Tariff Schedule of the United States Revision 15 (2026) Annotated for Statistical Reporting Purposes XXII 99 - III - 367